dentification and characterization of novel PAX4 variants in patients with suspected MODY9

Xinyu Chen1,2,3,4,5,6,7, Yang Tian1,3,4,5,6,7, Wanhong Wu1,3,4,5,6,7

  • 1Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.

PubMed
Abstract

Insights

Three novel PAX4 gene variants were identified in patients with Maturity-onset diabetes of the young (MODY). These PAX4 variants impair beta-cell function by destabilizing the protein, offering new insights into MODY9 pathogenesis.

Area of Science:

  • Genetics
  • Endocrinology
  • Molecular Biology

Background:

  • Maturity-onset diabetes of the young (MODY) is a monogenic diabetes.
  • MODY type 9 (MODY9) is caused by variants in the PAX4 gene.
  • Pathogenicity of many PAX4 variants remains unclear.

Purpose of the Study:

  • Evaluate clinical relevance of three novel PAX4 variants.
  • Investigate pathogenic mechanisms of these PAX4 variants.
  • Understand MODY9 pathogenesis.

Main Methods:

  • Whole-exome and Sanger sequencing identified PAX4 variants.
  • In silico predictions and structural modeling were performed.
  • Functional studies in MIN6 cells assessed protein expression and degradation.

Main Results:

  • Three novel PAX4 variants (p.Gln28ArgfsTer6, p.Leu12Pro, p.Arg163Pro) were identified.
  • Missense variants (p.Leu12Pro, p.Arg163Pro) showed reduced protein levels due to enhanced proteasomal degradation.
  • Nonsense variant (p.Gln28ArgfsTer6) was undetectable, likely via nonsense-mediated decay.

Conclusions:

  • Expands the spectrum of known PAX4 variants.
  • Provides mechanistic insights into MODY9 pathogenesis.
  • Highlights the importance of assessing protein-level consequences for variant interpretation.